The Benefits of IV IgG Replacement for BCMA Carty

In the pediatric population for whom only CD19 carty is approved for BAL, these patients have limited pre-established plasma cells to begin with. So in this case, they will resemble the BCMA carty even though they got a CD19 product. The expert recommendation for IV IgG replacement tends to be more liberated forBCMA carty recipients and for the pediatric CD19 cartY cell recipients as compared to adults who get CD19.